Who Buys Tamoxifen from India — 377 Importers Behind a $14.7M Market

The importation of Tamoxifen from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like ALIUD PHARMA GMBH in Germany and BELLS HEALTHCARE in the United Kingdom function as intermediaries, procuring Tamoxifen in bulk to supply to pharmacies, hospitals, and clinics. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as AUROBINDO PHARMA USA., INC and AUROLOGISTICS LLC in the United States import Tamoxifen for further processing or packaging before distribution. Their procurement is aligned with production schedules, leading to sizable, periodic orders.

• Retail Chains: Organizations like WOCKHARDT UK LIMITED and TILLOMED LABORATORIES LIMITED in the United Kingdom import Tamoxifen to stock their retail outlets. Their purchasing behavior is influenced by consumer demand, resulting in moderate, consistent orders to ensure product availability.

• Government Procurement: While not explicitly listed among the top buyers, government agencies and international organizations often engage in tender-based purchasing of essential medicines like Tamoxifen. Their procurement processes are typically large-scale and periodic, driven by public health initiatives and budget cycles.

• Re-exporters: Some buyers may import Tamoxifen with the intent to re-export to other markets. This segment's purchasing behavior is opportunistic, capitalizing on price differentials and market demands in various regions.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

Importing Tamoxifen into the top five countries involves navigating specific regulatory frameworks:

• United States:
• Regulatory Authority: Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure that Tamoxifen is FDA-approved and comply with the Drug Supply Chain Security Act (DSCSA).
• Estimated Timeline: The FDA approval process can take several months, depending on the completeness of the application and compliance with regulatory requirements.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049048 are generally duty-free, but importers should verify current tariffs with U.S. Customs and Border Protection.

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Tamoxifen must be registered with BfArM, and importers need a wholesale license.
• Estimated Timeline: Registration can take several months, contingent on the submission of required documentation and compliance with EU regulations.
• Import Tariff/Duty: As an EU member, Germany applies the Common External Tariff, which may impose duties on pharmaceuticals; importers should consult the latest EU tariff schedules.

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Importers must hold a Wholesale Dealer's License and ensure Tamoxifen is registered with the MHRA.
• Estimated Timeline: The registration process can take several months, depending on the complexity of the application and compliance with UK regulations.
• Import Tariff/Duty: Post-Brexit, the UK sets its own tariffs; importers should refer to the UK Global Tariff for current rates on HS Code 30049048.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Tamoxifen must be authorized by FAMHP, and importers require a distribution license.
• Estimated Timeline: Authorization can take several months, subject to the provision of necessary documentation and adherence to EU directives.
• Import Tariff/Duty: As part of the EU, Belgium applies the Common External Tariff; importers should check the latest EU tariff information for pharmaceuticals.

• Thailand:
• Regulatory Authority: Thai Food and Drug Administration (Thai FDA).
• Import Registration Process: Importers must obtain a license from the Thai FDA, and Tamoxifen must be registered before importation.
• Estimated Timeline: The registration process can take several months, depending on the completeness of the application and compliance with Thai regulations.
• Import Tariff/Duty: Thailand imposes import duties on pharmaceuticals; importers should consult the Thai Customs Department for current rates on HS Code 30049048.

Importers are advised to consult the respective regulatory authorities and customs departments for the most current and detailed information, as regulations and tariffs are subject to change.

The demand for Tamoxifen across importing countries is influenced by several key factors:

• Disease Prevalence: Tamoxifen is primarily used in the treatment and prevention of breast cancer. According to the World Health Organization (WHO), breast cancer remains the most common cancer among women worldwide, with approximately 2.3 million new cases diagnosed in 2025. This high prevalence drives consistent demand for effective treatments like Tamoxifen.

• Government Healthcare Programs: Many countries have implemented national health programs that subsidize or provide essential medicines to their populations. For instance, the United Kingdom's National Health Service (NHS) includes Tamoxifen in its formulary, ensuring widespread access.

• Universal Health Coverage Expansion: Countries expanding their universal health coverage are increasing access to essential medicines. Thailand's Universal Coverage Scheme, for example, has improved access to cancer treatments, including Tamoxifen, for its citizens.

• WHO Essential Medicines List Procurement: Tamoxifen is listed on the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement. This inclusion encourages governments and health organizations to stock Tamoxifen, ensuring its availability in public health systems.

• Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through tender processes to ensure cost-effectiveness and supply security. The WHO emphasizes the importance of tendering and negotiation in pharmaceutical procurement to achieve lower prices and reliable supply chains. (iris.who.int)

With 377 buyers across 104 countries, the global market for Tamoxifen is robust. The combination of high disease prevalence, supportive government policies, and strategic procurement practices presents significant market opportunities for suppliers.

The importation of Tamoxifen from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like ALIUD PHARMA GMBH in Germany and BELLS HEALTHCARE in the United Kingdom function as intermediaries, procuring Tamoxifen in bulk to supply to pharmacies, hospitals, and clinics. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as AUROBINDO PHARMA USA., INC and AUROLOGISTICS LLC in the United States import Tamoxifen for further processing or packaging before distribution. Their procurement is aligned with production schedules, leading to sizable, periodic orders.

• Retail Chains: Organizations like WOCKHARDT UK LIMITED and TILLOMED LABORATORIES LIMITED in the United Kingdom import Tamoxifen to stock their retail outlets. Their purchasing behavior is influenced by consumer demand, resulting in moderate, consistent orders to ensure product availability.

• Government Procurement: While not explicitly listed among the top buyers, government agencies and international organizations often engage in tender-based purchasing of essential medicines like Tamoxifen. Their procurement processes are typically large-scale and periodic, driven by public health initiatives and budget cycles.

• Re-exporters: Some buyers may import Tamoxifen with the intent to re-export to other markets. This segment's purchasing behavior is opportunistic, capitalizing on price differentials and market demands in various regions.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

Importing Tamoxifen into the top five countries involves navigating specific regulatory frameworks:

• United States:
• Regulatory Authority: Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure that Tamoxifen is FDA-approved and comply with the Drug Supply Chain Security Act (DSCSA).
• Estimated Timeline: The FDA approval process can take several months, depending on the completeness of the application and compliance with regulatory requirements.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049048 are generally duty-free, but importers should verify current tariffs with U.S. Customs and Border Protection.

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Tamoxifen must be registered with BfArM, and importers need a wholesale license.
• Estimated Timeline: Registration can take several months, contingent on the submission of required documentation and compliance with EU regulations.
• Import Tariff/Duty: As an EU member, Germany applies the Common External Tariff, which may impose duties on pharmaceuticals; importers should consult the latest EU tariff schedules.

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Importers must hold a Wholesale Dealer's License and ensure Tamoxifen is registered with the MHRA.
• Estimated Timeline: The registration process can take several months, depending on the complexity of the application and compliance with UK regulations.
• Import Tariff/Duty: Post-Brexit, the UK sets its own tariffs; importers should refer to the UK Global Tariff for current rates on HS Code 30049048.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Tamoxifen must be authorized by FAMHP, and importers require a distribution license.
• Estimated Timeline: Authorization can take several months, subject to the provision of necessary documentation and adherence to EU directives.
• Import Tariff/Duty: As part of the EU, Belgium applies the Common External Tariff; importers should check the latest EU tariff information for pharmaceuticals.

• Thailand:
• Regulatory Authority: Thai Food and Drug Administration (Thai FDA).
• Import Registration Process: Importers must obtain a license from the Thai FDA, and Tamoxifen must be registered before importation.
• Estimated Timeline: The registration process can take several months, depending on the completeness of the application and compliance with Thai regulations.
• Import Tariff/Duty: Thailand imposes import duties on pharmaceuticals; importers should consult the Thai Customs Department for current rates on HS Code 30049048.

Importers are advised to consult the respective regulatory authorities and customs departments for the most current and detailed information, as regulations and tariffs are subject to change.

The demand for Tamoxifen across importing countries is influenced by several key factors:

• Disease Prevalence: Tamoxifen is primarily used in the treatment and prevention of breast cancer. According to the World Health Organization (WHO), breast cancer remains the most common cancer among women worldwide, with approximately 2.3 million new cases diagnosed in 2025. This high prevalence drives consistent demand for effective treatments like Tamoxifen.

• Government Healthcare Programs: Many countries have implemented national health programs that subsidize or provide essential medicines to their populations. For instance, the United Kingdom's National Health Service (NHS) includes Tamoxifen in its formulary, ensuring widespread access.

• Universal Health Coverage Expansion: Countries expanding their universal health coverage are increasing access to essential medicines. Thailand's Universal Coverage Scheme, for example, has improved access to cancer treatments, including Tamoxifen, for its citizens.

• WHO Essential Medicines List Procurement: Tamoxifen is listed on the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement. This inclusion encourages governments and health organizations to stock Tamoxifen, ensuring its availability in public health systems.

• Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through tender processes to ensure cost-effectiveness and supply security. The WHO emphasizes the importance of tendering and negotiation in pharmaceutical procurement to achieve lower prices and reliable supply chains. (iris.who.int)

With 377 buyers across 104 countries, the global market for Tamoxifen is robust. The combination of high disease prevalence, supportive government policies, and strategic procurement practices presents significant market opportunities for suppliers.